--Abbott is testing several experimental hepatitis C drugs
--More than 90% of patients with no prior treatment in one study had suppressed virus 12 weeks after treatment
--Abbott is targeting launch of hepatitis C regimen in 2015
(Adds details of a Bristol-Myers study in final paragraph; updates stock prices.)
Experimental drugs from Abbott Laboratories (ABT) suppressed the hepatitis C virus in most patients in two small, midstage studies.
The results unveiled Wednesday could reinforce Abbott's position as a key player in an industry race to bring the next generation of drugs to what is expected to be a multibillion-dollar market
No comments:
Post a Comment